KLRC1 and neoplasm: Some inhibitory receptors and checkpoint molecules, such as NKG2A, TIGIT, and CBLB, blocking the NK cell activation, can be knocked out by CRISPR/Cas9 gene-editing technology to increase the anti-tumor cytotoxicity of NK-92 cells clones used for modification with CAR constructs [80].